FrancophonIA/ELRC3.0 huggingface dataset:
English: - certain skin cancers (keratoacanthoma/squamous cell carcinoma of the skin) - headache, confusion, seizures and visual loss associated with or without high blood pressure (posterior reversible encephalopathy syndrome/PRES) - serious reactions of the skin and/or mucous membranes which may include painful blisters and fever, including extensive detachment of the skin (Stevens-Johnson syndrome and toxic epidermal necrolysis).
Croatian: ozbiljne reakcije na koži i/ili sluznicama koje mogu uključivati bolne mjehure i vrućicu, kao i intenzivno odvajanje kože (Stevens-Johnsonov sindrom i toksičnu epidermalnu nekrolizu).
English: Figure 3: Kaplan-Meier curves of OS
Croatian: Slika 3: Kaplan-Meierove krivulje ukupnog preživljenja
English: Bayer S.p.A. Tel: +39-02-397 81
Croatian: Tel: +39-02-397 81
English: Placebo plus BSC§ (N=255)
Croatian: Placebo uz najbolju potpornu njegu (N=255)
English: Interrupt Stivarga treatment.
Croatian: Prekinite liječenje lijekom Stivarga.
English: NR**
Croatian: AUC-a).
English: Figure 4: Kaplan-Meier curve of OS
Croatian: Slika 4: Kaplan-Meierova krivulja ukupnog preživljenja
English: Figure 1: Kaplan-Meier curve of OS
Croatian: Slika 1: Kaplan-Meierova krivulja ukupnog preživljenja
English: Get medical help immediately, if you get the following symptoms: - passing blood in the stools or passing black stools - passing blood in the urine - stomach pain - coughing/vomiting up blood.
Croatian: Odmah potražite liječničku pomoć ako razvijete sljedeće simptome: pojavu krvi u stolici ili crnu boju stolice pojavu krvi u mokraći bol u trbuhu iskašljavanje / povraćanje krvi
English: No QTc prolonging effects were observed after administration of 160 mg regorafenib at steady state in a dedicated QT study in male and female cancer patients.
Croatian: U ispitivanju posvećenom samo utjecaju na QT interval u onkoloških bolesnika oba spola nisu opaženi učinci na produljenje QTc intervala u stanju dinamičke ravnoteže nakon primjene 160 mg regorafeniba.
English: PFS
Croatian: GGN
English: This can affect the way Stivarga works.
Croatian: To može utjecati na način djelovanja lijeka
English: Pain
Croatian: - bol
English: Contents of the pack and other information What Stivarga contains
Croatian: Što Stivarga sadrži
English: and fits (hypertensive crisis) - inflammation of the pancreas characterized by pain in the area of the stomach, nausea,
Croatian: upala gušterače karakterizirana boli u području trbuha, mučninom, povraćanjem i vrućicom
English: Get medical help immediately if you get the following symptoms: - high fever - severe cough with or without an increase in mucus (sputum) production - severe sore throat
Croatian: Potražite odmah liječničku pomoć ako razvijete sljedeće simptome: - jako povišena tjelesna temperatura - jaki kašalj s ili bez povećanog stvaranja sluzi (iskašljaj) - jaka grlobolja - nedostatak zraka - pečenje/bol prilikom mokrenja - neuobičajen vaginalni iscjedak ili nadraženost - crvenilo, oticanje i/ili bol u bilo kojem dijelu tijela.
English: Hypertensive crisis
Croatian: Rizični bolesnici
English: Placebo plus BSC§ (N=66)
Croatian: Placebo uz najbolju potpornu njegu (N=66)
English: Diarrhoea Stomatitis Vomiting Nausea
Croatian: Lijekovi za odjeljivanje žučnih soli
English: Grade
Croatian: Doziranje
English: Posology
Croatian: Postoci
English: Take special care with Stivarga
Croatian: Nastaviti s liječenjem lijekom Stivarga.
English: Any occurrence Discontinue treatment with Stivarga permanently.
Croatian: Ako nema nestanka promjena, primjenu lijeka Stivarga mora se trajno prekinuti.
English: Liver problems
Croatian: Ukupno preživljenje
English: Any occurrence
Croatian: pojavljivanje bilo koji put
English: Tell your doctor immediately if you have taken more than your prescribed dose.
Croatian: Ako ste uzeli više od propisane doze, odmah o tome obavijestite svog liječnika.
English: ORR**#
Croatian: stupanj*
English: General disorders and administration site conditions
Croatian: Common Terminology Criteria for Adverse
English: These include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy (see section 5.1)
Croatian: To uključuje kemoterapiju na bazi fluoropirimidina, anti-VEGF terapiju i anti-EGFR terapiju (vidjeti dio 5.1). - s inoperabilnim ili metastatskim gastrointestinalnim stromalnim tumorima (engl. gastrointestinal stromal tumours, GIST) u kojih je bolest dalje napredovala ili koji nisu podnosili prethodno liječenje imatinibom i sunitinibom.
English: Hyperbilirubinemia
Croatian: Bayer Vital GmbH
English: Leucopenia
Croatian: Dojenje
English: Hand-foot skin reaction** Rash
Croatian: Stopa objektivnog odgovora **#
English: Skin and subcutaneous tissue disorders
Croatian: Poremećaji bubrega i mokraćnog sustava proteinurija
English: Gastrointestinal perforation and fistula
Croatian: Rizični bolesnici Stivarga Placebo
English: - an enlargement and weakening of a blood vessel wall or a tear in a blood vessel wall (aneurysms and artery dissections).
Croatian: Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka) - proširenje i slabljenje stijenke krvne žile ili rascjep stijenke krvne žile (aneurizme i disekcije arterije).
English: Increase in amylase Increase in lipase Abnormal International normalised ratio
Croatian: visoke razine određenih enzima uključenih u probavu (povišenje amilaza i lipaza) poremećeno stanje zgrušavanja krvi (poremećen međunarodni normalizirani omjer)
English: Bayer AS Tlf.
Croatian: Magyarország Bayer Hungária Kft.
English: About 51% of those given Rydapt and 43% of those given placebo were still alive after 5 years.
Croatian: Otprilike 51 % bolesnika koji su primili Rydapt i 43 % onih koji su primili placebo bili su i dalje živi nakon pet godina.
English: The full EPAR for Rydapt can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za lijek Rydapt nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Overall, using the most stringent, up-to-date criteria, the disease responded to treatment in about 28% of patients (32 of 113).
Croatian: Ukupno gledano, koristeći se s najstrožim ažuriranim kriterijima, bolest je reagirala na liječenje u otprilike 28 % bolesnika (32 od 113).
English: What is Rydapt and what is it used for?
Croatian: Što je Rydapt i za što se koristi?
English: What measures are being taken to ensure the safe and effective use of Rydapt?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Rydapt?
English: The safety of the medicine was acceptable in such a severe condition and was considered manageable.
Croatian: Sigurnost lijeka bila je prihvatljiva za takvu ozbiljnu bolest te se smatralo da se njome može upravljati.
English: Other information about Rydapt
Croatian: Ostale informacije o lijeku Rydapt
English: This is a summary of the European public assessment report (EPAR) for Rydapt.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) lijeka Rydapt.
English: Although Rydapt had not been compared with other treatments, given the rarity of the conditions and the unmet medical need of patients who have them, the clinical benefits were clear, and the adverse effects acceptable.
Croatian: Iako Rydapt još nije uspoređen s ostalim vrstama liječenja, s obzirom na rijetkost tih bolesti i nezadovoljene medicinske potrebe bolesnika koji ih imaju, kliničke koristi bile su jasne, a nuspojave prihvatljive.
English: The company that markets Rydapt will complete three further studies to provide the Agency with evidence to support the effectiveness of the medicine in elderly patients with AML.
Croatian: Tvrtka koja stavlja na tržište lijek Rydapt dovršit će tri dodatna ispitivanja kako bi Agenciji pružila dokaze koji podupiru djelotvornost lijeka u starijih bolesnika s AML-om.
English: Treatment is continued for up to 12 cycles depending on how patients respond.
Croatian: Liječenje se nastavlja tijekom razdoblja od najviše 12 ciklusa, ovisno o reakciji bolesnika.
English: The usual starting dose is 50 mg (two capsules) twice a day for AML, on days 8 to 21 of a 28-day treatment cycle, and then every day once the disease has responded.
Croatian: Uobičajena početna doza iznosi 50 mg (dvije kapsule) dva puta dnevno za AML od 8. do 21. dana ciklusa liječenja od 28 dana, a nakon toga svakog dana nakon što bolest reagira na liječenje.
English: When looked at separately the response rate was highest (60%) in those with aggressive systemic mastocytosis.
Croatian: Zasebno gledano, stopa reakcije bila je najviša (60 %) u bolesnika s agresivnom sistemskom mastocitozom.
English: It is not intended to provide practical advice on how to use Rydapt.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni lijeka Rydapt.
English: What are the risks associated with Rydapt?
Croatian: Koji su rizici povezani s lijekom Rydapt?
English: The European Medicines Agency therefore decided that Rydapt's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Stoga je Europska agencija za lijekove zaključila da koristi lijeka Rydapt nadmašuju s njim povezane rizike i preporučila izdavanje odobrenja za njegovu primjenu u EU-u.
English: Rydapt must not be given to patients taking certain other medicines that affect the way it is handled in the body.
Croatian: Rydapt ne smije se primjenjivati u bolesnika koji uzimaju određene druge lijekove koji utječu na način njegove probave u organizmu.
English: This means that it blocks the action of certain enzymes known as receptor tyrosine kinases.
Croatian: To znači da blokira djelovanje određenih enzima poznatih pod nazivom tirozin-kinaze.
English: Another main study involving 116 patients with mast cell disorders also showed benefit.
Croatian: U drugom glavnom ispitivanju u kojem je sudjelovalo 116 bolesnika s poremećajima mastocita također je utvrđena korist.
English: Why is Rydapt approved?
Croatian: Zašto je lijek Rydapt odobren?
English: For mast cell disorders, the starting dose is 100 mg (four capsules) twice daily; treatment is continued for as long as the patient benefits.
Croatian: Početna doza za poremećaje mastocita iznosi 100 mg (četiri kapsule) dva puta dnevno, a liječenje se nastavlja sve dok bolesnik ima koristi od liječenja.
English: Because the number of patients with these diseases is low, they are considered ‘rare', and Rydapt was designated an ‘orphan medicine' (a medicine used in rare diseases) on various dates (see below).
Croatian: Budući da je broj bolesnika s tim bolestima nizak, one se smatraju „rijetkima”, a lijek Rydapt dobio je status „lijeka za liječenje rijetkih bolesti” na različite datume (vidjeti u nastavku).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Rydapt have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Rydapt nalaze se u sažetku opisa svojstava i u uputi o lijeku.
English: Rydapt is available as capsules containing 25 mg of midostaurin.
Croatian: Lijek Rydapt je dostupan u obliku kapsula koje sadržavaju 25 mg midostaurina.
English: Rydapt can only be obtained with a prescription and treatment should be started by a doctor experienced in the use of cancer medicines.
Croatian: Lijek Rydapt se izdaje samo na liječnički recept, a liječenje bi trebao započeti liječnik s iskustvom primjene lijekova za liječenje raka.
English: For more information about treatment with Rydapt, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Rydapt pročitajte u uputi o lijeku (također dio EPAR-a), odnosno obratite se svom liječniku ili ljekarniku.
English: By blocking the abnormal FLT3 enzyme, Rydapt helps to bring about the death of the abnormal cells and control the spread of the cancer.
Croatian: Blokiranjem abnormalnog FLT3 enzima, Rydapt pridonosi odumiranju abnormalnih stanica i kontroli širenja raka.
English: One main study, involving 717 such patients, compared Rydapt with placebo (a dummy treatment) initially as an addition to other cancer medicines, followed by treatment with Rydapt or placebo alone in those whose disease responded.
Croatian: Lijek Rydapt je u okviru jednog glavnog ispitivanja, u kojem je sudjelovalo 717 takvih bolesnika, uspoređen s placebom (prividno liječenje) prvo u kombinaciji s ostalim lijekovima za liječenje raka, a zatim kao monoterapija lijekom Rydapt ili placebom u bolesnika čija je bolest reagirala na liječenje.
English: Rydapt is only given when the AML has a particular genetic change called an FLT3 mutation.
Croatian: Lijek Rydapt primjenjuje se samo ako AML ima posebnu genetsku promjenu koja se naziva FLT3 mutacija.
English: In patients with an FLT3 mutation, an abnormal form of the FLT3 tyrosine kinase stimulates the survival and growth of AML cells.
Croatian: U bolesnika s FLT3 mutacijom abnormalni oblik FLT3 tirozin-kinaze stimulira preživljavanje i rast stanica AML-a.
English: It is used with other cancer medicines (chemotherapy) initially and on its own once the chemotherapy is completed if the disease has responded to treatment.
Croatian: U početku se primjenjuje u kombinaciji s ostalim lijekovima za liječenje raka (kemoterapija) te kao monoterapija nakon dovršetka kemoterapije ako je bolest reagirala na liječenje.
English: For practical information about using Rydapt, patients should read the package leaflet or contact their doctor or pharmacist.
Croatian: Praktične informacije o primjeni lijeka Rydapt bolesnici trebaju pročitati u uputi o lijeku, odnosno obratiti se svom liječniku ili ljekarniku.
English: Rydapt also blocks a mutated form of another enzyme, KIT kinase, which plays an important role in stimulating the abnormal growth of mast cells in patients with mast cell disorders.
Croatian: Lijek Rydapt također inhibira mutirani oblik jednog drugog enzima, KIT kinaze, koji ima važnu ulogu u stimuliranju abnormalnog rasta mastocita u bolesnika s poremećajima mastocita.
English: How is Rydapt used?
Croatian: Kako se Rydapt koristi?
English: What benefits of Rydapt have been shown in studies?
Croatian: Koje su koristi lijeka Rydapt utvrđene u ispitivanjima?
English: The active substance in Rydapt, midostaurin, is a ‘tyrosine kinase inhibitor'.
Croatian: Djelatna tvar lijeka Rydapt, midostaurin, inhibitor je tirozin-kinaze.
English: In mast cell disorders there was also important evidence of effectiveness.
Croatian: Također su pruženi važni dokazi o učinkovitosti u pogledu poremećaja mastocita.
English: When used for mast cell disorders, the commonest side effects (affecting one third or more of all patients) were nausea, vomiting, diarrhoea, peripheral oedema (swelling of the ankles and feet) and tiredness.
Croatian: Kada se primjenjuje za poremećaje mastocita, najčešće nuspojave (javljaju se kod jedne trećine ili više svih bolesnika) bile su mučnina, povraćanje, proljev, periferni edem (oticanje zglobova i stopala) i umor.
English: When used to treat AML, the most common side effects with Rydapt (which may affect more than 1 in 10 people) are febrile neutropenia (fever and low white blood cell count, seen in nearly all patients), exfoliative dermatitis (inflamed, peeling skin), vomiting, headache, petechiae (tiny blood spots under the skin) and fever.
Croatian: Kada se primjenjuje za liječenje AML-a, najčešće nuspojave lijeka Rydapt (koje se mogu javiti u više od 1 od 10 osoba) jesu neutropenija praćena vrućicom (vrućica i nizak broj bijelih krvnih stanica, zabilježeni kod gotovo svih bolesnika), eksfolijativni dermatitis (upaljena koža koja se ljušti), povraćanje, glavobolja, petehije (mala točkasta potkožna krvarenja) i vrućica.
English: For the full list of all side effects reported with Rydapt, see the package leaflet.
Croatian: Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Rydapt potražite u uputi o lijeku.
English: Rydapt is a cancer medicine used to treat adults with newly diagnosed acute myeloid leukaemia (AML), a cancer of white blood cells.
Croatian: Rydapt je lijek za liječenje raka koji koristi za liječenje odraslih osoba s novodijagnosticiranom akutnom mijeloičnom leukemijom (ALM), vrstom raka bijelih krvnih stanica.
English: The study looked at the response to Rydapt treatment in patients with aggressive systemic mastocytosis, systemic mastocytosis associated with blood cancer, or mast cell leukaemia.
Croatian: Ispitivanje se bavilo reakcijom na terapiju lijekom Rydapt u bolesnika s agresivnom sistemskom mastocitozom, sistemskom mastocitozom povezanom s rakom krvi ili mastocitnom leukemijom.
English: The most frequent severe side effects were febrile neutropenia, lymphopenia (low counts of lymphocytes, a particular type of white blood cell), infections at the site of a catheter (a tube inserted in a vein), exfoliative dermatitis, high blood sugar and nausea (feeling sick).
Croatian: Najčešće ozbiljne nuspojave bile su neutropenija praćena vrućicom, limfopenija (nizak broj limfocita, posebne vrste bijelih krvnih stanica), infekcije na mjestu uvođenja katetera (cjevčice umetnute u venu) eksfolijativni dermatitis, visoke razine šećera u krvi i mučnina (slabost).
English: The commonest severe side effects were tiredness, sepsis (blood poisoning), pneumonia (lung infection), febrile neutropenia and diarrhoea.
Croatian: Najčešće nuspojave bile su umor, sepsa (trovanje krvi), pneumonija (upala pluća), neutropenija s vrućicom i proljev.
English: Rydapt is also used on its own in adults with the following disorders of a type of white blood cell known as mast cell: aggressive systemic mastocytosis, systemic mastocytosis associated with a haematological neoplasm (blood cancer), and mast cell leukaemia.
Croatian: Lijek Rydapt također se primjenjuje kao monoterapija u odraslih bolesnika sa sljedećim poremećajima povezanim s mastocitima, vrstom bijelih krvnih stanica: agresivnom sistemskom mastocitozom, sistemskom mastocitozom s povezanom hematološkom neoplazmom (rak krvi) i mastocitnom leukemijom.
English: Rydapt has been shown to improve survival in patients with AML associated with an FLT3 mutation.
Croatian: Utvrđeno je da lijek Rydapt poboljšava preživljavanje bolesnika oboljelih od AML-a s FLT3 mutacijom.
English: Rydapt contains the active substance midostaurin.
Croatian: Lijek Rydapt sadržava djelatnu tvar midostaurin.
English: The summaries of the opinion of the Committee for Orphan Medicinal Products for Rydapt can be found on the Agency's website:
Croatian: Sažetak mišljenja Odbora za lijekove za rijetke bolesti o lijeku Rydapt nalazi se na internetskim stranicama Agencije: akutna mijeloična leukemija, mastocitoza.
English: Rydapt has been shown to be of benefit in patients with AML associated with an FTL3 mutation.
Croatian: Utvrđeno je bolesnici oboljelih od AML-a s FLT3 mutacijom imaju koristi od lijeka Rydapt.
English: --1 Influenza virus (inactivated, split) of the following strains*:
Croatian: --1 Virus influence (inaktiviran, fragmentiran) sljedećih sojeva*:
English: A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A) ....... 15 micrograms HA** A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B) .
Croatian: A/California/7/2009 (H1N1)pdm09 - sličan soj (A/California/7/2009, NYMC X-179A) ...... 15 mikrograma HA** A/Hong Kong/4801/2014 (H3N2) - sličan soj (A/Hong Kong/4801/2014, NYMC X-263B) 15 mikrograma HA** B/Brisbane/60/2008 - sličan soj (B/Brisbane/60/2008, divlji tip) ............................................ 15 mikrograma HA**
English: Per 0.1 ml dose * propagated in fertilised hens' eggs from healthy chicken flocks ** haemagglutinin l t o r
Croatian: Po dozi od 0,1 ml * umnoženi na oplođenim kokošjim jajima od zdravih pilećih jata ** hemaglutinin k i
English: Invented name Strength
Croatian: (Zaštićeno) ime Doza
English: PritorPlus is taken by mouth once a day with liquid, with or without food.
Croatian: PritorPlus se uzima kroz usta jednom na dan s tekućinom, uz ili bez obroka.
English: PritorPlus must not be used in women who are more than three months pregnant.
Croatian: PritorPlus ne smiju uzimati žene koje su trudne dulje od tri mjeseca.
English: Other information about PritorPlus
Croatian: Ostale informacije o lijeku PritorPlus
English: What measures are being taken to ensure the safe and effective use of PritorPlus?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka PritorPlus?
English: PritorPlus has been studied in five main studies involving a total of 2,985 patients with mild to moderate hypertension.
Croatian: PritorPlus je ispitivan u pet glavnih ispitivanja kojima je obuhvaćeno ukupno 2985 bolesnika s umjerenom hipertenzijom.
English: The European Commission granted a marketing authorisation valid throughout the European Union for PritorPlus on 22 April 2002.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek PritorPlus na snazi u Europskoj uniji od 22. travnja 2002.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for PritorPlus.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet te preporuke o uvjetima za primjenu lijeka PritorPlus.
English: This is a summary of the European public assessment report (EPAR) for PritorPlus.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku PritorPlus.
English: The most common side effect with PritorPlus (seen in between 1 and 10 patients in 100) is dizziness.
Croatian: Najčešća nuspojava lijeka PritorPlus (uočena kod više od 10 na 100 bolesnika) je vrtoglavica.
English: PritorPlus telmisartan / hydrochlorothiazide
Croatian: PritorPlus telmisartan/hidroklorotiazid
English: A risk management plan has been developed to ensure that PritorPlus is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka PritorPlus.
English: What is the risk associated with PritorPlus?
Croatian: Koji su rizici povezani s lijekom PritorPlus?
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for PritorPlus, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek PritorPlus nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, PritorPlus must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Croatian: U bolesnika s tipom 2 dijabetesa ili u bolesnika s umjerenim ili ozbiljnim oštećenjem funkcije bubrega, PritorPlus se ne smije koristiti u kombinaciji s lijekovima koji sadrže aliskiren (također se koristi za liječenje esencijalne hipertenzije).
English: Care must be taken when using PritorPlus with other medicines that have an effect on blood potassium levels.
Croatian: Potreban je oprez prilikom primjene lijeka PritorPlus s drugim lijekovima koji utječu na razinu kalija u krvi.
English: Telmisartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Croatian: PritorPlus je „antagonist receptora angiotenzina II”, što znači da blokira rad hormona angiotenzina II u tijelu.
English: What is PritorPlus?
Croatian: Što je PritorPlus?
English: Why has PritorPlus been approved?
Croatian: Zašto je PritorPlus odobren?